China SXT Pharmaceuticals (SXTC) Operating Leases (2023 - 2026)

China SXT Pharmaceuticals (SXTC) has reported Operating Leases for 4 consecutive years, with $53442.0 the latest figure, recorded in Q1 2026.

• Quarterly Operating Leases fell 53.7% year-over-year to $53442.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53442.0 (down 53.7% YoY) and the FY2026 annual result came in at $53442.0, down 53.7% from the prior year.
• Operating Leases slipped to $53442.0 in Q1 2026 per SXTC's latest filing, from $85161.0 in the prior quarter.
• Over the last five years, Operating Leases for SXTC reached as high as $306050.0 in Q1 2023 and fell as low as $53442.0 in Q1 2026.
• A 4-year average of $164305.0 and a median of $149278.0 in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2024 — Operating Leases declined 22.94% — and 2026, when it sank 53.7%.
• Year by year, Operating Leases stood at $204937.0 in 2023, then decreased by 27.16% to $149278.0 in 2024, then plunged by 42.95% to $85161.0 in 2025, then tumbled by 37.25% to $53442.0 in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $53442.0, $85161.0, and $115419.0 for Q1 2026, Q3 2025, and Q1 2025 respectively.